0

Close
 
Upcoming Allied Market Research
2023
Veterinary Anti-infective Market

Veterinary Anti-Infective Market: Global Opportunity Analysis and Industry Forecast, 2023-2030 Market

LS : Healthcare
Report Code: A11238
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Veterinary Anti-infective Market

Request Now !

The veterinary anti-infective is a broad criterion, wherein the animals are taken care by ensuring both the prevention and curative methods for the disease. There are various infections caused to the animals which are food borne or even Zoonotic diseases. The animal types which are focused in the veterinary anti-infective include the cats, dogs, cattle, poultry and others. Furthermore the several types of drugs which can be used for the treatment of these diseases based on the requirement. The spread of the diseases is also would prevent infectious agents or organisms from spreading. The zoonotic disease affect the human too and hence requires precautionary measures for safety.

Veterinary-Anit-Infective

COVID-19 scenario analysis:

The COVID-19 impact is affecting the healthcare systems worldwide. Increase in need for healthcare facilities and healthcare workers are being observed in the forecast period. The pandemic cases are observed to be caused because of direct or indirect contact between humans. The animals aren’t proved to be spreading the disease but the pets are getting abandoned in the current scenario. Furthermore, COVID-19 has weakened the supply chain and has created shortage of animal health products such as nutritional feed as well as vaccines. The animal health industry has been impacted negatively, as manufacturers in animal health industry are left with a significantly reduced workforce.

Healthcare facilities are stocking up the animal related health products, considering the high demand. This is anticipated to further create financial strain on the market due to procurement inefficiencies and wasted speeding. Due to the pandemic situation, many hospitals and veterinary clinics are overstocking the products.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

The key factor that is anticipated to boost the industry includes the increase in the incidences of the infectious and zoonotic diseases. The growth in the need for the precautionary measures and the treatment is also expected to help the market propel in the coming years. Furthermore, the increase in R&D activities in animal health tends to help in boosting the industry. The rise in the food borne diseases, which may be caused due to the contamination of food would help in the market growth in the forecast period. The surge in the pet-ownership would help the industry flourish.

New product advancements to flourish the market

In September 2019, Team Vetoquinol India launched Antibiotic Wound dressing spray (Aluspray AWD) in July-2019. This is the product for applying on wound, which acts as protective physical and chemical barrier stopping the infection and keep the dirt and bacteria out while allowing the wound to heal faster. Launch demonstrations were done by Vetoquinol team to Veterinary practitioners across India. The product was also demonstrated to canine practitioners, academicians and progressive dairy farmers. The product is available in two presentations 125 ML for Large animal and 75 ML for Small animal use.

In November 2019, a new consortium of research institutes, universities, not-for-profit organizations, and pharmaceutical companies have teamed up to develop novel drugs for infections caused by parasitic worms (helminthes), a debilitating group of diseases that includes river blindness, lymphatic filariasis as well as infection with hookworm and whipworm, which together affect close to a billion people.

Surge in mergers and acquisitions to boost the market

In May 2018, Zoetis Inc. and Abaxis, Inc. announced a definitive merger agreement pursuant to which Zoetis acquired Abaxis, a leader in the development, manufacture and marketing of diagnostic instruments for veterinary point-of-care services for $83 per share in cash, or approximately $2.0 billion in aggregate. The acquisition is expected to enhance Zoetis’ presence in veterinary diagnostics, a category of the animal health industry with approximately 10% compound annual growth over the last three years.

This acquisition brings Zoetis a company that has a proven, competitive diagnostic platform for growth that we can help to accelerate in the U.S. and worldwide with our global scale and direct customer relationships in approximately 45 countries.

Key benefits of the report:

  • This study presents the analytical depiction of the global veterinary anti-infective industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global veterinary anti-infective market share.
  • The current market is quantitatively analyzed to highlight the global veterinary anti-infective market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the veterinary anti-infective market.
  • The report provides a detailed global veterinary anti-infective market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the veterinary anti-infective market research report:

  • Who are the leading market players active in the Veterinary Anti-Infective market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in tasking further strategic steps?

 Veterinary Anti-Infective Market: Global Opportunity Analysis and Industry Forecast, 2020–2027 Report Highlights

Aspects Details
By Animal Type
  • Dogs
  • Cattle
  • Poultry
  • Cats
  • Others
By Product Type
  • Antifungals
  • Antibacterial
  • Antivirals
  • Others
By Mode of Administration
  • Topical
  • Oral
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Rest of LAMEA)
Key Market Players Sanofi (Merial Animal Health), Cipla Limited, Neogen Corporation, Dechra Pharmaceuticals PLC, Phibro Animal Health Corporation, Vetoquinol S.A., Heska Corp (Diamond Animal Health), Merck & Co., Inc. (Merck Animal Health), Bayer AG, Eli Lilly and Company (Elanco Animal Health)
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: VETERINARY ANTI-INFECTIVE MARKET, BY ANIMAL TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Animal Type

    • 4.2. Dogs

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Cattle

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Poultry

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Cats

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Others

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: VETERINARY ANTI-INFECTIVE MARKET, BY PRODUCT TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Product Type

    • 5.2. Antifungals

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Antibacterial

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Antivirals

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Others

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: VETERINARY ANTI-INFECTIVE MARKET, BY MODE OF ADMINISTRATION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Mode Of Administration

    • 6.2. Topical

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Oral

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Others

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: VETERINARY ANTI-INFECTIVE MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Animal Type

      • 7.2.3. Market Size and Forecast, By Product Type

      • 7.2.4. Market Size and Forecast, By Mode Of Administration

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Veterinary Anti-infective Market

        • 7.2.6.1. Market Size and Forecast, By Animal Type
        • 7.2.6.2. Market Size and Forecast, By Product Type
        • 7.2.6.3. Market Size and Forecast, By Mode Of Administration

      • 7.2.7. Canada Veterinary Anti-infective Market

        • 7.2.7.1. Market Size and Forecast, By Animal Type
        • 7.2.7.2. Market Size and Forecast, By Product Type
        • 7.2.7.3. Market Size and Forecast, By Mode Of Administration

      • 7.2.8. Mexico Veterinary Anti-infective Market

        • 7.2.8.1. Market Size and Forecast, By Animal Type
        • 7.2.8.2. Market Size and Forecast, By Product Type
        • 7.2.8.3. Market Size and Forecast, By Mode Of Administration

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Animal Type

      • 7.3.3. Market Size and Forecast, By Product Type

      • 7.3.4. Market Size and Forecast, By Mode Of Administration

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Veterinary Anti-infective Market

        • 7.3.6.1. Market Size and Forecast, By Animal Type
        • 7.3.6.2. Market Size and Forecast, By Product Type
        • 7.3.6.3. Market Size and Forecast, By Mode Of Administration

      • 7.3.7. Germany Veterinary Anti-infective Market

        • 7.3.7.1. Market Size and Forecast, By Animal Type
        • 7.3.7.2. Market Size and Forecast, By Product Type
        • 7.3.7.3. Market Size and Forecast, By Mode Of Administration

      • 7.3.8. Italy Veterinary Anti-infective Market

        • 7.3.8.1. Market Size and Forecast, By Animal Type
        • 7.3.8.2. Market Size and Forecast, By Product Type
        • 7.3.8.3. Market Size and Forecast, By Mode Of Administration

      • 7.3.9. Spain Veterinary Anti-infective Market

        • 7.3.9.1. Market Size and Forecast, By Animal Type
        • 7.3.9.2. Market Size and Forecast, By Product Type
        • 7.3.9.3. Market Size and Forecast, By Mode Of Administration

      • 7.3.10. UK Veterinary Anti-infective Market

        • 7.3.10.1. Market Size and Forecast, By Animal Type
        • 7.3.10.2. Market Size and Forecast, By Product Type
        • 7.3.10.3. Market Size and Forecast, By Mode Of Administration

      • 7.3.11. Russia Veterinary Anti-infective Market

        • 7.3.11.1. Market Size and Forecast, By Animal Type
        • 7.3.11.2. Market Size and Forecast, By Product Type
        • 7.3.11.3. Market Size and Forecast, By Mode Of Administration

      • 7.3.12. Rest Of Europe Veterinary Anti-infective Market

        • 7.3.12.1. Market Size and Forecast, By Animal Type
        • 7.3.12.2. Market Size and Forecast, By Product Type
        • 7.3.12.3. Market Size and Forecast, By Mode Of Administration

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Animal Type

      • 7.4.3. Market Size and Forecast, By Product Type

      • 7.4.4. Market Size and Forecast, By Mode Of Administration

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Veterinary Anti-infective Market

        • 7.4.6.1. Market Size and Forecast, By Animal Type
        • 7.4.6.2. Market Size and Forecast, By Product Type
        • 7.4.6.3. Market Size and Forecast, By Mode Of Administration

      • 7.4.7. Japan Veterinary Anti-infective Market

        • 7.4.7.1. Market Size and Forecast, By Animal Type
        • 7.4.7.2. Market Size and Forecast, By Product Type
        • 7.4.7.3. Market Size and Forecast, By Mode Of Administration

      • 7.4.8. India Veterinary Anti-infective Market

        • 7.4.8.1. Market Size and Forecast, By Animal Type
        • 7.4.8.2. Market Size and Forecast, By Product Type
        • 7.4.8.3. Market Size and Forecast, By Mode Of Administration

      • 7.4.9. South Korea Veterinary Anti-infective Market

        • 7.4.9.1. Market Size and Forecast, By Animal Type
        • 7.4.9.2. Market Size and Forecast, By Product Type
        • 7.4.9.3. Market Size and Forecast, By Mode Of Administration

      • 7.4.10. Australia Veterinary Anti-infective Market

        • 7.4.10.1. Market Size and Forecast, By Animal Type
        • 7.4.10.2. Market Size and Forecast, By Product Type
        • 7.4.10.3. Market Size and Forecast, By Mode Of Administration

      • 7.4.11. Thailand Veterinary Anti-infective Market

        • 7.4.11.1. Market Size and Forecast, By Animal Type
        • 7.4.11.2. Market Size and Forecast, By Product Type
        • 7.4.11.3. Market Size and Forecast, By Mode Of Administration

      • 7.4.12. Malaysia Veterinary Anti-infective Market

        • 7.4.12.1. Market Size and Forecast, By Animal Type
        • 7.4.12.2. Market Size and Forecast, By Product Type
        • 7.4.12.3. Market Size and Forecast, By Mode Of Administration

      • 7.4.13. Indonesia Veterinary Anti-infective Market

        • 7.4.13.1. Market Size and Forecast, By Animal Type
        • 7.4.13.2. Market Size and Forecast, By Product Type
        • 7.4.13.3. Market Size and Forecast, By Mode Of Administration

      • 7.4.14. Rest of Asia Pacific Veterinary Anti-infective Market

        • 7.4.14.1. Market Size and Forecast, By Animal Type
        • 7.4.14.2. Market Size and Forecast, By Product Type
        • 7.4.14.3. Market Size and Forecast, By Mode Of Administration

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Animal Type

      • 7.5.3. Market Size and Forecast, By Product Type

      • 7.5.4. Market Size and Forecast, By Mode Of Administration

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Veterinary Anti-infective Market

        • 7.5.6.1. Market Size and Forecast, By Animal Type
        • 7.5.6.2. Market Size and Forecast, By Product Type
        • 7.5.6.3. Market Size and Forecast, By Mode Of Administration

      • 7.5.7. South Africa Veterinary Anti-infective Market

        • 7.5.7.1. Market Size and Forecast, By Animal Type
        • 7.5.7.2. Market Size and Forecast, By Product Type
        • 7.5.7.3. Market Size and Forecast, By Mode Of Administration

      • 7.5.8. Saudi Arabia Veterinary Anti-infective Market

        • 7.5.8.1. Market Size and Forecast, By Animal Type
        • 7.5.8.2. Market Size and Forecast, By Product Type
        • 7.5.8.3. Market Size and Forecast, By Mode Of Administration

      • 7.5.9. UAE Veterinary Anti-infective Market

        • 7.5.9.1. Market Size and Forecast, By Animal Type
        • 7.5.9.2. Market Size and Forecast, By Product Type
        • 7.5.9.3. Market Size and Forecast, By Mode Of Administration

      • 7.5.10. Argentina Veterinary Anti-infective Market

        • 7.5.10.1. Market Size and Forecast, By Animal Type
        • 7.5.10.2. Market Size and Forecast, By Product Type
        • 7.5.10.3. Market Size and Forecast, By Mode Of Administration

      • 7.5.11. Rest of LAMEA Veterinary Anti-infective Market

        • 7.5.11.1. Market Size and Forecast, By Animal Type
        • 7.5.11.2. Market Size and Forecast, By Product Type
        • 7.5.11.3. Market Size and Forecast, By Mode Of Administration

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Bayer AG

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Cipla Limited

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Dechra Pharmaceuticals PLC

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Eli Lilly And Company (Elanco Animal Health)

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Heska Corp (Diamond Animal Health)

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Merck And Co., Inc. (Merck Animal Health)

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Neogen Corporation

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Phibro Animal Health Corporation

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Sanofi (Merial Animal Health)

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Vetoquinol S.A.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL VETERINARY ANTI-INFECTIVE MARKET, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL VETERINARY ANTI-INFECTIVE MARKET FOR DOGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL VETERINARY ANTI-INFECTIVE MARKET FOR CATTLE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL VETERINARY ANTI-INFECTIVE MARKET FOR POULTRY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL VETERINARY ANTI-INFECTIVE MARKET FOR CATS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL VETERINARY ANTI-INFECTIVE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL VETERINARY ANTI-INFECTIVE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL VETERINARY ANTI-INFECTIVE MARKET FOR ANTIFUNGALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL VETERINARY ANTI-INFECTIVE MARKET FOR ANTIBACTERIAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL VETERINARY ANTI-INFECTIVE MARKET FOR ANTIVIRALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL VETERINARY ANTI-INFECTIVE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL VETERINARY ANTI-INFECTIVE MARKET, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL VETERINARY ANTI-INFECTIVE MARKET FOR TOPICAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL VETERINARY ANTI-INFECTIVE MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL VETERINARY ANTI-INFECTIVE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL VETERINARY ANTI-INFECTIVE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA VETERINARY ANTI-INFECTIVE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 21. U.S. VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 22. U.S. VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 23. U.S. VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 24. CANADA VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 25. CANADA VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 26. CANADA VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE VETERINARY ANTI-INFECTIVE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 37. GERMANY VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 38. GERMANY VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 39. GERMANY VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 40. ITALY VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 41. ITALY VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 42. ITALY VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 46. UK VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 47. UK VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 48. UK VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 49. RUSSIA VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 50. RUSSIA VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 51. RUSSIA VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 52. REST OF EUROPE VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 53. REST OF EUROPE VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 54. REST OF EUROPE VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC VETERINARY ANTI-INFECTIVE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 56. ASIA-PACIFIC VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 57. ASIA-PACIFIC VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 58. ASIA-PACIFIC VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 59. CHINA VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 60. CHINA VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 61. CHINA VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 62. JAPAN VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 63. JAPAN VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 64. JAPAN VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 65. INDIA VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 66. INDIA VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 67. INDIA VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 70. SOUTH KOREA VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 71. AUSTRALIA VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 72. AUSTRALIA VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 73. AUSTRALIA VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 74. THAILAND VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 75. THAILAND VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 76. THAILAND VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 77. MALAYSIA VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 78. MALAYSIA VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 79. MALAYSIA VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 80. INDONESIA VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 81. INDONESIA VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 82. INDONESIA VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 85. REST OF ASIA PACIFIC VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 86. LAMEA VETERINARY ANTI-INFECTIVE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 87. LAMEA VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 88. LAMEA VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 89. LAMEA VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 90. BRAZIL VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 91. BRAZIL VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 92. BRAZIL VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 93. SOUTH AFRICA VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH AFRICA VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH AFRICA VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 96. SAUDI ARABIA VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 97. SAUDI ARABIA VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 98. SAUDI ARABIA VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 99. UAE VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 100. UAE VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 101. UAE VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 102. ARGENTINA VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 103. ARGENTINA VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 104. ARGENTINA VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 105. REST OF LAMEA VETERINARY ANTI-INFECTIVE, BY ANIMAL TYPE, 2022-2032 ($MILLION)
  • TABLE 106. REST OF LAMEA VETERINARY ANTI-INFECTIVE, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 107. REST OF LAMEA VETERINARY ANTI-INFECTIVE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 108. BAYER AG: KEY EXECUTIVES
  • TABLE 109. BAYER AG: COMPANY SNAPSHOT
  • TABLE 110. BAYER AG: OPERATING SEGMENTS
  • TABLE 111. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 112. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. CIPLA LIMITED: KEY EXECUTIVES
  • TABLE 114. CIPLA LIMITED: COMPANY SNAPSHOT
  • TABLE 115. CIPLA LIMITED: OPERATING SEGMENTS
  • TABLE 116. CIPLA LIMITED: PRODUCT PORTFOLIO
  • TABLE 117. CIPLA LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. DECHRA PHARMACEUTICALS PLC: KEY EXECUTIVES
  • TABLE 119. DECHRA PHARMACEUTICALS PLC: COMPANY SNAPSHOT
  • TABLE 120. DECHRA PHARMACEUTICALS PLC: OPERATING SEGMENTS
  • TABLE 121. DECHRA PHARMACEUTICALS PLC: PRODUCT PORTFOLIO
  • TABLE 122. DECHRA PHARMACEUTICALS PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 123. ELI LILLY AND COMPANY (ELANCO ANIMAL HEALTH): KEY EXECUTIVES
  • TABLE 124. ELI LILLY AND COMPANY (ELANCO ANIMAL HEALTH): COMPANY SNAPSHOT
  • TABLE 125. ELI LILLY AND COMPANY (ELANCO ANIMAL HEALTH): OPERATING SEGMENTS
  • TABLE 126. ELI LILLY AND COMPANY (ELANCO ANIMAL HEALTH): PRODUCT PORTFOLIO
  • TABLE 127. ELI LILLY AND COMPANY (ELANCO ANIMAL HEALTH): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 128. HESKA CORP (DIAMOND ANIMAL HEALTH): KEY EXECUTIVES
  • TABLE 129. HESKA CORP (DIAMOND ANIMAL HEALTH): COMPANY SNAPSHOT
  • TABLE 130. HESKA CORP (DIAMOND ANIMAL HEALTH): OPERATING SEGMENTS
  • TABLE 131. HESKA CORP (DIAMOND ANIMAL HEALTH): PRODUCT PORTFOLIO
  • TABLE 132. HESKA CORP (DIAMOND ANIMAL HEALTH): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 133. MERCK AND CO., INC. (MERCK ANIMAL HEALTH): KEY EXECUTIVES
  • TABLE 134. MERCK AND CO., INC. (MERCK ANIMAL HEALTH): COMPANY SNAPSHOT
  • TABLE 135. MERCK AND CO., INC. (MERCK ANIMAL HEALTH): OPERATING SEGMENTS
  • TABLE 136. MERCK AND CO., INC. (MERCK ANIMAL HEALTH): PRODUCT PORTFOLIO
  • TABLE 137. MERCK AND CO., INC. (MERCK ANIMAL HEALTH): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 138. NEOGEN CORPORATION: KEY EXECUTIVES
  • TABLE 139. NEOGEN CORPORATION: COMPANY SNAPSHOT
  • TABLE 140. NEOGEN CORPORATION: OPERATING SEGMENTS
  • TABLE 141. NEOGEN CORPORATION: PRODUCT PORTFOLIO
  • TABLE 142. NEOGEN CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 143. PHIBRO ANIMAL HEALTH CORPORATION: KEY EXECUTIVES
  • TABLE 144. PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT
  • TABLE 145. PHIBRO ANIMAL HEALTH CORPORATION: OPERATING SEGMENTS
  • TABLE 146. PHIBRO ANIMAL HEALTH CORPORATION: PRODUCT PORTFOLIO
  • TABLE 147. PHIBRO ANIMAL HEALTH CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 148. SANOFI (MERIAL ANIMAL HEALTH): KEY EXECUTIVES
  • TABLE 149. SANOFI (MERIAL ANIMAL HEALTH): COMPANY SNAPSHOT
  • TABLE 150. SANOFI (MERIAL ANIMAL HEALTH): OPERATING SEGMENTS
  • TABLE 151. SANOFI (MERIAL ANIMAL HEALTH): PRODUCT PORTFOLIO
  • TABLE 152. SANOFI (MERIAL ANIMAL HEALTH): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 153. VETOQUINOL S.A.: KEY EXECUTIVES
  • TABLE 154. VETOQUINOL S.A.: COMPANY SNAPSHOT
  • TABLE 155. VETOQUINOL S.A.: OPERATING SEGMENTS
  • TABLE 156. VETOQUINOL S.A.: PRODUCT PORTFOLIO
  • TABLE 157. VETOQUINOL S.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY ANTI-INFECTIVE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL VETERINARY ANTI-INFECTIVE MARKET
  • FIGURE 3. SEGMENTATION VETERINARY ANTI-INFECTIVE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN VETERINARY ANTI-INFECTIVE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALVETERINARY ANTI-INFECTIVE MARKET
  • FIGURE 11. VETERINARY ANTI-INFECTIVE MARKET SEGMENTATION, BY BY ANIMAL TYPE
  • FIGURE 12. VETERINARY ANTI-INFECTIVE MARKET FOR DOGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. VETERINARY ANTI-INFECTIVE MARKET FOR CATTLE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. VETERINARY ANTI-INFECTIVE MARKET FOR POULTRY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. VETERINARY ANTI-INFECTIVE MARKET FOR CATS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. VETERINARY ANTI-INFECTIVE MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. VETERINARY ANTI-INFECTIVE MARKET SEGMENTATION, BY BY PRODUCT TYPE
  • FIGURE 18. VETERINARY ANTI-INFECTIVE MARKET FOR ANTIFUNGALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. VETERINARY ANTI-INFECTIVE MARKET FOR ANTIBACTERIAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. VETERINARY ANTI-INFECTIVE MARKET FOR ANTIVIRALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. VETERINARY ANTI-INFECTIVE MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. VETERINARY ANTI-INFECTIVE MARKET SEGMENTATION, BY BY MODE OF ADMINISTRATION
  • FIGURE 23. VETERINARY ANTI-INFECTIVE MARKET FOR TOPICAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. VETERINARY ANTI-INFECTIVE MARKET FOR ORAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. VETERINARY ANTI-INFECTIVE MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 27. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 28. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 29. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 30. COMPETITIVE DASHBOARD
  • FIGURE 31. COMPETITIVE HEATMAP: VETERINARY ANTI-INFECTIVE MARKET
  • FIGURE 32. Top player positioning, 2022
  • FIGURE 33. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. BAYER AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. BAYER AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. CIPLA LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. CIPLA LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. CIPLA LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. DECHRA PHARMACEUTICALS PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. DECHRA PHARMACEUTICALS PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. DECHRA PHARMACEUTICALS PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. ELI LILLY AND COMPANY (ELANCO ANIMAL HEALTH): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. ELI LILLY AND COMPANY (ELANCO ANIMAL HEALTH): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. ELI LILLY AND COMPANY (ELANCO ANIMAL HEALTH): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. HESKA CORP (DIAMOND ANIMAL HEALTH): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. HESKA CORP (DIAMOND ANIMAL HEALTH): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. HESKA CORP (DIAMOND ANIMAL HEALTH): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. MERCK AND CO., INC. (MERCK ANIMAL HEALTH): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. MERCK AND CO., INC. (MERCK ANIMAL HEALTH): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. MERCK AND CO., INC. (MERCK ANIMAL HEALTH): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. NEOGEN CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. NEOGEN CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. NEOGEN CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. PHIBRO ANIMAL HEALTH CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. PHIBRO ANIMAL HEALTH CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. PHIBRO ANIMAL HEALTH CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. SANOFI (MERIAL ANIMAL HEALTH): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. SANOFI (MERIAL ANIMAL HEALTH): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. SANOFI (MERIAL ANIMAL HEALTH): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 60. VETOQUINOL S.A.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. VETOQUINOL S.A.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 62. VETOQUINOL S.A.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Veterinary Anti-infective Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers